MTVA vs IMMR vs MVIS vs VUZI

For growth investors, Vuzix Corporation (VUZI) is the stronger pick with 1090% revenue growth year-over-year, versus -74.

3% for MicroVision, Inc. (MVIS). Immersion Corporation (IMMR) offers the better valuation at 1. 6x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Immersion Corporation (IMMR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immersion Corporation (IMMR) delivered a total return of -6.

1%, compared to -95. 6% for MicroVision, Inc. (MVIS). Over 10 years, the gap is even starker: IMMR returned +13. 3% versus MVIS's -66. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MetaVia Inc.

(MTVA) is the lower-risk stock at 0. 67β versus Vuzix Corporation's 3. 40β — meaning VUZI is approximately 405% more volatile than MTVA relative to the S&P 500. On balance sheet safety, MetaVia Inc. (MTVA) carries a lower debt/equity ratio of 2% versus 66% for MicroVision, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vuzix Corporation (VUZI) is pulling ahead at 1090% versus -74.

3% for MicroVision, Inc. (MVIS). On earnings-per-share growth, the picture is similar: Immersion Corporation grew EPS 295. 2% year-over-year, compared to -44. 7% for MetaVia Inc.. Over a 3-year CAGR, VUZI leads at 709. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immersion Corporation (IMMR) is the more profitable company, earning 7.

3% net margin versus -78. 6% for MicroVision, Inc. — meaning it keeps 7. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMMR leads at 10. 7% versus -57. 4% for MVIS. At the gross margin level — before operating expenses — IMMR leads at 29. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MVIS: 711.

7% to $5. 00.

In this comparison, VUZI (10.

1% yield), IMMR (6. 0% yield) pay a dividend. MTVA, MVIS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, MetaVia Inc.

(MTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67)). MicroVision, Inc. (MVIS) carries a higher beta of 2. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTVA: -47. 4%, MVIS: -66. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MTVA (Healthcare) and IMMR (Technology) and MVIS (Technology) and VUZI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MTVA is a small-cap quality compounder stock; IMMR is a small-cap high-growth stock; MVIS is a small-cap quality compounder stock; VUZI is a small-cap high-growth stock. IMMR, VUZI pay a dividend while MTVA, MVIS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.